Please assess the completion status of the following clinical trial:

Trial Title: Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection~* Tuberculin skin test (TST) reactivity greater than or equal to 5 mm or a positive interferon gamma release assay (IGRA) at any time prior to study entry, OR living in a high TB burden area. More information on this criterion can be found in the protocol.~* Laboratory values obtained within 30 days prior to study entry:~  1. Absolute neutrophil count (ANC) greater than 750 cells/mm\^3~ 2. Hemoglobin greater than or equal to 7.4 g/dL~ 3. Platelet count greater than or equal to 50,000/mm\^3~ 4. AST (SGOT) and ALT (SGPT) less than or equal to three times the upper limit of normal (ULN)~ 5. Total bilirubin less than or equal to 2.5 times the ULN~* Chest radiograph or chest CT scan without evidence of active tuberculosis, unless one has been performed within 30 days prior to entry~* Female participants of reproductive potential must have a negative serum or urine pregnancy test performed within 7 days prior to study entry. More information on this criterion can be found in the protocol.~* All participants must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization) while receiving RPT and for 6 weeks after stopping this drug~* Female participants who are participating in sexual activity that could lead to pregnancy must agree to use one reliable non-hormonal form of contraceptive while receiving RPT and for 6 weeks after stopping this drug. More information on this criterion can be found in the protocol.~* Weight of greater than or equal to 30 kg~* Participant or legal guardian is able and willing to provide informed consent~Exclusion Criteria:~* Treatment for active or latent TB (pulmonary or extrapulmonary) within 2 years prior to study entry or, at screening, presence of any confirmed or probable TB based on criteria listed in the current ACTG Diagnosis Appendix~* History of multi-drug resistant (MDR) or extensively-drug resistant (XDR) TB at any time prior to study entry~* Known exposure to MDR or XDR TB (e.g., household member of a person with MDR or XDR TB) at any time prior to study entry~* Treatment for more than 14 consecutive days with a rifamycin or more than 30 consecutive days with INH at any time during the 2 years prior to enrollment~* For participants taking antiretroviral therapy (ART) at study entry, only approved nucleoside reverse transcriptase inhibitors (NRTIs) with efavirenz (EFV) or nevirapine (NVP) for at least 4 weeks were permitted~* History of liver cirrhosis at any time prior to study entry.~* Evidence of acute hepatitis, such as abdominal pain, jaundice, dark urine, and/or light stools within 90 days prior to study entry~* Diagnosis of porphyria at any time prior to study entry~* Peripheral neuropathy greater than or equal to Grade 2 according to the December 2004 (Clarification, August 2009) Division of AIDS (DAIDS) Toxicity Table, within 90 days prior to study entry~* Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation~* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements~* Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to study entry~* Breastfeeding

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RPT plus INH Regimen (Arm A) (Type: EXPERIMENTAL): Participants received RPT (dosage based on their weight), 300 mg of INH, and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 4. During Weeks 5 to 36, participants did not receive any study medications.
- INH Regimen (Arm B) (Type: ACTIVE_COMPARATOR): Participants received 300 mg of INH and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 36.

Based on this trial design, predict the completion outcome and termination type (if applicable).